300. IgG4関連疾患 [臨床試験数:31,薬物数:33(DrugBank:16),標的遺伝子数:11,標的パスウェイ数:81

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04660565
(ClinicalTrials.gov)
January 202123/9/2020Belimumab Treatment for IgG4-related DiseaseBelimumab Treatment for IgG4-related Disease, a Prospective, Open-label Clinical TrialIgG4-related DiseaseDrug: Prednisone and Belimumab;Drug: PrednisonePeking Union Medical College HospitalNULLRecruiting18 Years75 YearsAll60Phase 4China
2NCT02703194
(ClinicalTrials.gov)
March 201627/2/2016Leflunomide for Maintenance of Remission in IgG4 Related DiseaseA Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related DiseaseImmunoglobulin G4 Related Sclerosing DiseaseDrug: Prednisone;Drug: LeflunomideChinese PLA General HospitalNULLCompleted18 Years80 YearsAll68Phase 4China
3NCT02458196
(ClinicalTrials.gov)
April 201515/4/2015Study of Treatment Response on IgG4 Related Disease (IgG4RD)A Randomized Trial of Treatment in Patients With IgG4-Related DiseaseAutoimmune DiseaseDrug: Prednisone;Drug: Prednisone and Mycophenolate mofetilPeking Union Medical College HospitalNULLRecruiting18 Years70 YearsAll60Phase 2China
4NCT01758393
(ClinicalTrials.gov)
December 201224/12/2012Glucocorticoids in Patients With IgG4-RDA Randomized Trial of Glucocorticoids in Patients With IgG4-Related DiseaseIgG4-related DiseaseDrug: PrednisonePeking Union Medical College HospitalNULLRecruiting18 Years70 YearsBoth40Phase 2/Phase 3China